{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:53:56Z","timestamp":1777874036652,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cjca.2025.10.005","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:14Z","timestamp":1760145134000},"page":"346-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current State of Drug Therapies for Antibody-mediated Rejection After Heart Transplantation"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4434-584X","authenticated-orcid":false,"given":"Erik","family":"Henricksen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krysta","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Lichvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2025.10.005_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1053-2498(02)00472-2","article-title":"Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease","volume":"22","author":"Michaels","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.healun.2013.08.011","article-title":"The 2013 International Society for Heart and Lung Transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation","volume":"32","author":"Berry","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib3","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","article-title":"Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection","volume":"24","author":"Stewart","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.healun.2025.02.1690","article-title":"Summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation","volume":"44","author":"Kobashigawa","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jca.20129","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis","volume":"22","author":"Szczepiorkowski","year":"2007","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.cjca.2025.10.005_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12028-020-00989-1","article-title":"Drug dosing in patients undergoing therapeutic plasma exchange","volume":"34","author":"Mahmoud","year":"2021","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.cjca.2025.10.005_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosissup.2015.02.022","article-title":"Immunoadsorption with regenerating systems in neurological disorders---a single center experience","volume":"18","author":"Hohenstein","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.cjca.2025.10.005_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eclinm.2019.10.017","article-title":"Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: a randomised, parallel-group, controlled trial","volume":"16","author":"Dorst","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cjca.2025.10.005_bib9","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis---Part II: Non-kidney transplant","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109782","article-title":"Intravenous immunoglobulin in kidney transplantation: mechanisms of action, clinical applications, adverse effects, and hyperimmune globulin","volume":"256","author":"Hou","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cjca.2025.10.005_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cjca.2025.10.005_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.healun.2022.10.015","article-title":"The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients","volume":"42","author":"Velleca","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIR.0000000000000093","article-title":"Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association","volume":"131","author":"Colvin","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.10.005_bib14","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1111\/ajt.15922","article-title":"Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab","volume":"20","author":"Jordan","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib15","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl","key":"10.1016\/j.cjca.2025.10.005_bib16","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.healun.2009.11.320","article-title":"307: The effectiveness of a standardized desensitization protocol in reducing calculated panel reactive antibodies (cPRA) in sensitized heart transplant candidates: does it make sense to desensitize?","volume":"29","author":"Patel","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib17","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1161\/CIR.0000000000000598","article-title":"Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association","volume":"139","author":"Colvin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.10.005_bib18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00007890-199809270-00017","article-title":"Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action","volume":"66","author":"Jordan","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14524","article-title":"Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donor-specific antibody levels","volume":"36","author":"Yopes","year":"2022","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2004-13301","article-title":"In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody","volume":"13","author":"Sidner","year":"2004","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.cjca.2025.10.005_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2025.10.005_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/TP.0000000000003686","article-title":"Obinutuzumab in kidney transplantation: effect on B-cell counts and crossmatch tests","volume":"106","author":"Nasr Allah","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib26","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib27","author":"Choi"},{"key":"10.1016\/j.cjca.2025.10.005_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.healun.2004.09.003","article-title":"Treatment of vascular rejection with rituximab in cardiac transplantation","volume":"24","author":"Garrett","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib30","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.transproceed.2006.03.024","article-title":"Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab","volume":"38","author":"Keren","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cjca.2025.10.005_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.healun.2007.01.027","article-title":"Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review","volume":"26","author":"Kaczmarek","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib32","first-page":"901","article-title":"Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient","volume":"39","author":"Aggarwal","year":"2012","journal-title":"Texas Heart Inst J"},{"key":"10.1016\/j.cjca.2025.10.005_bib33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/ctr.12277","article-title":"Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review","volume":"27","author":"Ravichandran","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s11748-017-0763-3","article-title":"Successful management of antibody-mediated rejection after cardiac transplantation in a patient supported by a left ventricular assist device for more than 3 years","volume":"65","author":"Akiyama","year":"2017","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cjca.2025.10.005_bib35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/00007890-200203270-00013","article-title":"Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report","volume":"73","author":"Aranda","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib36","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1016\/j.transproceed.2004.10.087","article-title":"Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab","volume":"36","author":"Baran","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cjca.2025.10.005_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7182\/pit2015934","article-title":"Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report","volume":"25","author":"Gazdic","year":"2015","journal-title":"Prog Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/ki.2011.502","article-title":"Proteasome inhibitor-based therapy for antibody-mediated rejection","volume":"81","author":"Walsh","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2025.10.005_bib39","article-title":"Prescribing information","year":"2022","journal-title":"Takeda Pharmaceuticals"},{"key":"10.1016\/j.cjca.2025.10.005_bib40","series-title":"Prescribing information","year":"2022"},{"key":"10.1016\/j.cjca.2025.10.005_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15132","article-title":"Reduction of HLA donor specific antibodies in heart transplant patients treated with proteasome inhibitors for antibody mediated rejection","volume":"37","author":"Horn","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib42","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2025.10.005_bib43","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/TP.0b013e318218e901","article-title":"Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition","volume":"91","author":"Walsh","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib44","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1097\/TP.0000000000000706","article-title":"Acute rejection clinically defined phenotypes correlate with long-term renal allograft survival","volume":"99","author":"Krisl","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.seminhematol.2012.04.008","article-title":"Proteasome inhibition for antibody-mediated allograft rejection","volume":"493","author":"Sadaka","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.cjca.2025.10.005_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/TP.0000000000002049","article-title":"The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis","volume":"102","author":"Wan","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib48","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1097\/TP.0000000000003145","article-title":"Reducing donor-specific antibody during acute rejection diminishes long-term renal allograft loss: comparison of early and late rejection","volume":"104","author":"Lichvar","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/TP.0b013e31823f7eea","article-title":"Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients","volume":"93","author":"Morrow","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/TP.0b013e318257acf6","article-title":"Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients","volume":"94","author":"Schmidt","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib54","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1089\/ars.2014.5892","article-title":"Review of bortezomib treatment of antibody-mediated rejection in renal transplantation","volume":"21","author":"Ejaz","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.cjca.2025.10.005_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2025.14343","article-title":"Targeting CD38 in antibody-mediated rejection","volume":"38","author":"Mayer","year":"2025","journal-title":"Transplant Int"},{"key":"10.1016\/j.cjca.2025.10.005_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajt.2024.10.005","article-title":"Antiplasma cell antibodies: a new era of human leukocyte antigen antibody control in solid organ transplantation","volume":"25","author":"Chandran","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib57","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2025.10.005_bib58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.cjca.2025.10.005_bib59","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.healun.2025.02.041","article-title":"Impact of daratumumab on antibody mediated rejection in heart transplant recipients","volume":"44","author":"Sriwattanakomen","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib60","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/TP.0000000000003505","article-title":"Daratumumab for antibody-mediated rejection in heart transplant---a novel therapy: successful treatment of antibody-mediated rejection","volume":"105","author":"Aguilera Agudo","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib61","series-title":"Prescribing information","year":"2024"},{"key":"10.1016\/j.cjca.2025.10.005_bib62","article-title":"Prescribing information","year":"2025","journal-title":"Alexion Pharmaceuticals"},{"key":"10.1016\/j.cjca.2025.10.005_bib63","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib64","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib65","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.16420","article-title":"Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients","volume":"21","author":"Patel","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib66","article-title":"The use of eculizumab as a bridge to retransplantation for chronic antibody-mediated rejection in a heart transplant recipient: a case report","volume":"5","author":"Kearney","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.cjca.2025.10.005_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14454","article-title":"Eculizumab for antibody-mediated rejection in heart transplantation: a case-control study","volume":"35","author":"Kittleson","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib68","article-title":"Prescribing information","year":"2024","journal-title":"Alexion Pharmaceuticals"},{"key":"10.1016\/j.cjca.2025.10.005_bib69","series-title":"Product monograph. Hoffman-La Roche","year":"2022"},{"key":"10.1016\/j.cjca.2025.10.005_bib70","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.4049\/jimmunol.1401190","article-title":"Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production","volume":"194","author":"Chavele","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.cjca.2025.10.005_bib71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.trim.2013.03.003","article-title":"Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization","volume":"28","author":"Wu","year":"2013","journal-title":"Transplant Immunol"},{"key":"10.1016\/j.cjca.2025.10.005_bib72","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","article-title":"A phase I\/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib73","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/TP.0000000000004784","article-title":"Feasibility of interleukin-6 receptor blockade in cardiac antibody-mediated rejection","volume":"108","author":"Pottebaum","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib75","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cjca.2025.10.005_bib76","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.healun.2022.04.002","article-title":"A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation","volume":"41","author":"Kim","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib77","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1111\/ajt.15339","article-title":"Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study","volume":"19","author":"Khush","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14699","article-title":"Combining donor derived cell free DNA and gene expression profiling for non-invasive surveillance after heart transplantation","volume":"37","author":"Henricksen","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/TP.0000000000004323","article-title":"The molecular microscope diagnostic system: assessment of rejection and injury in heart transplant biopsies","volume":"107","author":"Halloran","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.cjca.2025.10.005_bib80","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1111\/ajt.15863","article-title":"Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: from bench to bedside","volume":"20","author":"Butler","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjca.2025.10.005_bib81","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.34067\/KID.0000000000000509","article-title":"New therapies for highly sensitized patients on the waiting list","volume":"5","author":"Vo","year":"2024","journal-title":"Kidney360"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25012073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25012073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:50:34Z","timestamp":1777575034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X25012073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0828282X25012073"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.10.005","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current State of Drug Therapies for Antibody-mediated Rejection After Heart Transplantation","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}